Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,034 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo 400 mg Clear all
Completed Phase 2 Interventional

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

NCT01626573
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Itacitinib, Itacitinib Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Palm Desert, California • Pasadena, California • Lake Mary, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 7, 2026, 10:47 AM EDT
Recruiting Not applicable Interventional

Randomized Evaluation of Natural Extract for Menopausal Wellness (RENEW)

NCT07834463
View directory record Official record
Conditions
Menopause, Hot Flashes
Interventions
Shatavari (Asparagus racemosus) Extract, Placebo
Dietary Supplement · Other
Lead sponsor
India Glycols Ltd
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Port Richey, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Inflammation and Daily Life Study

NCT03771612
View directory record Official record
Conditions
Inflammation
Interventions
Naproxen, Placebos
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
45 Years to 60 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia

NCT00596011
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Polyphenon E, Placebo
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
30 Years to 80 Years · Male only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
10
States / cities
Gainesville, Florida • Jacksonville, Florida • Lakeland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 7, 2026, 10:47 AM EDT
Terminated Phase 3 Interventional Results available

Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

NCT05079230
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Magrolimab, Venetoclax, Azacitidine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
39
States / cities
Little Rock, Arkansas • Duarte, California • Fresno, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 2 Interventional

Calcium and Vitamin D vs Markers of Adenomatous Polyps

NCT00208793
View directory record Official record
Conditions
Colorectal Adenomatous Polyps
Interventions
Calcium and vitamin D3 combined, Placebo, Calcium, Vitamin D3
Dietary Supplement · Drug
Lead sponsor
Emory University
Other
Eligibility
30 Years to 74 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 7, 2026, 10:47 AM EDT
Terminated Phase 2 Interventional

Research Study for Patients With Metastatic Renal Cell Carcinoma

NCT00110344
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Nexavar (Sorafenib, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

NCT01353729
View directory record Official record
Conditions
Influenza, Human
Interventions
600 mg zanamivir + moxifloxacin placebo, 1200 mg zanamivir + moxifloxacin placebo, zanamivir placebo + moxifloxacin placebo, zanamivir placebo + 400 mg moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of Gepotidacin

NCT04493931
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin, Cimetidine, Rifampicin, Midazolam, Digoxin, Placebo matching to gepotidacin
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors

NCT01508702
View directory record Official record
Conditions
Gout
Interventions
lesinurad, Placebo
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
79
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT04177108
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Atezolizumab, Ipatasertib, Paclitaxel, Placebo for Atezolizumab, Placebo for Ipatasertib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
31
States / cities
Mobile, Alabama • Springdale, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

NCT00717236
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol (CZP), Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
101
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cervical Preparation Before Dilation and Evacuation

NCT01751087
View directory record Official record
Conditions
Abortion, Induced
Interventions
Mifepristone, misoprostol, Osmotic dilators, placebo
Other · Drug · Device
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

NCT01328821
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
CTP-499
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 3 Interventional

A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes

NCT00076232
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity, Herpes Genitalis
Interventions
Acyclovir, Acyclovir placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
3,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
San Francisco, California • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 30, 2010 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

NCT03224351
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659, TEZ/IVA, IVA, Placebo (matched to VX-659/TEZ/IVA), TEZ, VX-561, Placebo (matched to VX-659/TEZ/VX-561)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers

NCT05099510
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Natrunix, Placebo
Biological
Lead sponsor
XBiotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects

NCT04505397
View directory record Official record
Conditions
Healthy
Interventions
SKL24741, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 7, 2026, 10:47 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of MEB-1170 in Healthy Subjects

NCT05748119
View directory record Official record
Conditions
Pain
Interventions
MEB-1170, Placebo
Drug
Lead sponsor
Mebias Discovery, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 7, 2026, 10:47 AM EDT
Recruiting Phase 2 Interventional

Belimumab With Rituximab for Primary Membranous Nephropathy

NCT03949855
View directory record Official record
Conditions
Membranous Nephropathy, Nephrotic Syndrome
Interventions
Belimumab, Placebo for Belimumab, Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 7, 2026, 10:47 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

NCT06981078
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Verekitug, Placebo
Drug · Other
Lead sponsor
Upstream Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Bakersfield, California • Encino, California • Lomita, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD

NCT03247543
View directory record Official record
Conditions
ADHD
Interventions
Placebo, 200mg SPN-812, 400mg SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Long Beach, California • Lauderhill, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 7, 2026, 10:47 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The Effects of Vitamin E and Vitamin C and Exercise

NCT01369043
View directory record Official record
Conditions
Exercise and Non-exercise Effect Upon Vitamins E and C
Interventions
Vitamin E and Vitamin C
Dietary Supplement
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
30 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 1 Interventional

Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

NCT04027387
View directory record Official record
Conditions
HIV-1-infection
Interventions
TMB-365
Biological
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
San Francisco, California • Ft. Pierce, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 7, 2026, 10:47 AM EDT